Investment Summary

Niox Group PLC is a specialty respiratory diagnostics company focused on the development and commercialisation of FeNO (fractional exhaled nitric oxide) testing devices used in the diagnosis and management of asthma and related airway conditions. The company's NIOX VERO and NIOX VERO Junior devices are the global standard for FeNO measurement, supported by extensive clinical evidence, regulatory clearances and inclusion in major asthma management guidelines. With rising recognition of the role of FeNO testing in personalised asthma management, expanding Biologics use in severe asthma and continued investment in commercial reach, Niox offers an attractive opportunity to invest in respiratory diagnostics. The combination of strong margins, recurring consumables Revenue and an asset-light Business model supports our positive view. We rate the shares a Buy.

Business Overview

Niox is headquartered in London, United Kingdom, and is listed on the London Stock Exchange AIM market. The company designs, develops, manufactures and commercialises FeNO testing devices and associated consumables and accessories. The flagship NIOX VERO device provides a non-invasive, point-of-care measurement of fractional exhaled nitric oxide, a validated biomarker of type 2 (eosinophilic) airway inflammation. NIOX VERO Junior is designed for paediatric patients. The product portfolio also includes single-use breathing handle consumables required for each FeNO test, calibration accessories and software support tools.

The customer base includes primary care practices, pulmonary specialist clinics, allergy clinics, paediatric clinics and hospital outpatient departments across the United States, the United Kingdom, Continental Europe, Japan, Canada and many other countries. Commercial operations include direct sales in major markets and distributor partnerships in additional geographies, supported by clinical education, medical affairs and Customer Service teams.

Sector Backdrop

Asthma is one of the most common chronic respiratory conditions globally, affecting more than 300 million people. Despite the prevalence and availability of effective therapies, many patients remain poorly controlled, with significant healthcare system costs and quality of life impact. Modern asthma management increasingly emphasises phenotypic understanding, with type 2 eosinophilic asthma representing a major subset that responds particularly well to targeted biologic therapies such as anti-IgE, anti-IL-5 and anti-TSLP agents. FeNO testing provides a non-invasive, point-of-care biomarker of type 2 inflammation that supports diagnosis, treatment selection, biologic eligibility assessment, adherence monitoring and step-up/step-down treatment decisions. Major asthma management guidelines, including those from the National Institute for Health and Care Excellence (NICE), the Global Initiative for Asthma (GINA) and various national guidelines, increasingly support FeNO testing as part of standard asthma diagnosis and management. Growing use of biologic therapies in severe asthma further reinforces the role of FeNO testing as a companion biomarker.

Investment Thesis

Our positive view on Niox rests on several pillars. First, the company is the global leader in FeNO testing, with the NIOX VERO platform being the gold standard for clinical and research use, supported by extensive clinical evidence and regulatory clearances. Second, the business model combines instrument sales with high-Margin consumables revenue, providing growing Recurring Revenue contribution as the installed base expands. Third, secular trends including the growing use of FeNO in asthma management guidelines, the expanding role of biologics in severe asthma and increased awareness of personalised asthma care support multi-year Demand growth. Fourth, the company has been investing in geographic expansion, particularly in the United States and selected European markets, supporting accelerating revenue growth. Fifth, profitability is strong, with attractive gross margins, expanding operating margins and high free Cash Flow conversion. Sixth, the Balance Sheet is robust, supporting continued investment, dividends and potential bolt-on opportunities. Seventh, the valuation embeds limited Credit for the structural growth runway and continued Operating Leverage.

Growth Drivers

Several specific drivers reinforce the medium-term outlook. The growing installed base of NIOX VERO devices supports recurring consumables revenue at high incremental margins. New device sales continue to grow as more clinics adopt FeNO testing and existing customers expand utilisation. The United States represents a particularly significant growth opportunity, with FeNO testing penetration still well below potential and ongoing payer coverage expansion supporting clinical adoption. Inclusion of FeNO testing in updated clinical guidelines, including the GINA 2024 update and various national asthma management frameworks, supports prescriber adoption. The expanding biologic therapies pipeline in severe asthma, including newer agents targeting different aspects of type 2 inflammation, supports demand for FeNO testing as a companion biomarker for treatment selection and monitoring. New product development, including next-generation device features and digital health integration, supports continued differentiation. Geographic expansion in select markets including Asia Pacific provides additional growth corridors.

Financial Performance

Niox has delivered consistent revenue growth supported by both device sales and consumables. Reported revenues have grown at attractive rates, with consumables revenue, in particular, providing recurring momentum. Gross margins are strong, in the high 60s to low 70s percent range, reflecting the differentiated technology, regulatory positioning and the relative absence of direct competing products. Adjusted EBITDA margins are typically in the high 20s to low 30s percent range, with continued operating leverage providing scope for further margin expansion as revenue scales. Free cash flow conversion is high, supported by limited Capital/">Working Capital and disciplined Capital Expenditure. The balance sheet is in a strong position, with net cash providing flexibility for continued investment, progressive dividends and potential M&A. Medium-term financial guidance reflects continued revenue and Earnings growth supported by the structural drivers and operational discipline.

Consumables revenue is the structural quality lever in the financial model. Each FeNO test requires a single-use breathing handle, providing recurring purchase requirements tied directly to device utilisation. As the installed base of NIOX VERO devices grows, consumables revenue scales naturally, supporting a high-quality, predictable revenue stream. Higher consumables revenue also lifts overall blended gross margins, as consumables typically carry higher margins than the underlying device sales. The combination of installed base growth and consumables expansion creates a virtuous cycle of compounding revenue and margin progression. This 'razor and blade' model is one of the most attractive characteristics of the business and supports our positive view on the medium-term financial trajectory.

Clinical Evidence and Regulatory Positioning

Niox's market Leadership is supported by extensive clinical evidence, regulatory clearances and inclusion in major guidelines. The NIOX VERO platform has been used in hundreds of clinical studies across asthma, allergic rhinitis, eosinophilic disorders, COPD overlap conditions, paediatric respiratory disease and pulmonary inflammation more broadly. Regulatory clearances include FDA, CE Mark, Health Canada, Japanese PMDA and many other national approvals. Inclusion in clinical guidelines, including NICE asthma diagnosis guidance in the UK, GINA global asthma management guidelines and various national respiratory frameworks, provides important commercial support and reinforces prescriber and payer acceptance. Continued investment in clinical research, real-world evidence and health economic studies supports the ongoing case for FeNO testing as a standard of care in asthma management.

Commercialisation Outlook

Niox commercialises its products through direct sales teams in major markets including the United States, the United Kingdom, Germany, France and other European countries, complemented by distributor partnerships in additional geographies. Clinical education, key opinion leader engagement, scientific presentations at major respiratory conferences and physician Training programmes support adoption. Digital Marketing, customer success initiatives and customer support services strengthen long-term customer relationships and consumables utilisation. The expanding biologic therapies market in severe asthma supports commercial partnerships with biopharmaceutical companies looking to position their therapies in the appropriate type 2 inflammation patient phenotype, supported by FeNO testing. Continued investment in commercial capability is expected to drive further growth, particularly in the United States.

Dividend and Capital Returns

Niox has begun returning capital to shareholders, supported by strong free cash flow and a healthy balance sheet. The dividend policy includes a regular annual distribution that has been growing alongside earnings. Special dividends and share Buybacks have been used periodically to return surplus capital. The strong cash conversion of the business and the asset-light nature of operations support continued capital return alongside reinvestment in commercial expansion, product development and selective bolt-on opportunities. For investors seeking a combination of growth and capital returns within specialty diagnostics, Niox provides an attractive profile.

Valuation Perspective

Niox trades on a valuation that reflects its quality, growth profile and balance sheet strength, but in our view does not fully capture the structural growth runway, US opportunity or operating leverage potential. Forward earnings multiples are reasonable relative to specialty medical device peers, and EV/EBITDA metrics support an attractive entry point. Discounted cash flow analysis incorporating conservative growth and margin assumptions points to meaningful upside from current levels. As US revenue continues to grow, biologic therapy use expands and operating leverage continues to deliver, the financial profile should strengthen further, supporting potential re-rating.

Key Risks

Risks include competitive developments, including potential entry of alternative FeNO testing platforms or competing biomarkers; reimbursement dynamics for FeNO testing in major markets; clinical guideline updates that could affect the role of FeNO testing in asthma management; Manufacturing Supply reliability for breathing handle consumables and device components; foreign exchange Volatility given international revenue exposure; macroeconomic conditions affecting healthcare provider purchasing decisions; and the timing of biologic therapy market expansion which influences companion biomarker testing demand. Patent and intellectual property protection across the device platform is important to maintaining the competitive position.

Sustainability and ESG

Niox supports better respiratory health outcomes through more accurate asthma diagnosis and management. The company emphasises environmental management at manufacturing facilities, including energy efficiency and waste reduction, alongside investment in sustainable design across products and packaging. Strong governance, ethical compliance, transparent reporting and engagement with patient advocacy and respiratory care communities support broader stakeholder relations. The mission of improving respiratory disease management contributes to broader public health objectives and ESG positioning.

Strategic Repositioning and Focus

Niox Group has undergone a meaningful strategic repositioning over recent years, including the divestment of its non-core therapeutics activities to focus exclusively on the FeNO diagnostics business. This sharper focus has allowed the leadership team to direct capital, management bandwidth and operational resources towards the highest-returning aspect of the business. The simplified operating model is more efficient to manage, easier for investors to evaluate and better positioned to capture the structural growth opportunity in FeNO testing. Following the strategic simplification, the company returned substantial capital to shareholders through tender offers, special dividends and ongoing share buybacks, demonstrating discipline and Shareholder alignment in capital allocation.

The focused operating model also enables more efficient investment in commercial expansion, particularly in the United States, where the FeNO testing opportunity is large but penetration remains well below potential. By concentrating resources on the highest-priority growth corridor, the company can build commercial scale more rapidly and capture share gains in a market where awareness, payer coverage and clinical adoption are all expanding. The combination of strategic clarity, operational discipline and shareholder alignment provides a strong framework for the medium-term outlook.

Conclusion: Why We Rate Niox Group a Buy

Niox Group PLC is the global leader in FeNO testing, exposed to structural growth in personalised asthma management, expanding biologic therapy use and increasing inclusion of FeNO in clinical guidelines. With strong margins, recurring consumables revenue, a robust balance sheet, a progressive dividend policy and continued operating leverage, the company is well placed to deliver attractive long-term value creation. The valuation provides a reasonable entry point and continued execution should support a re-rating. We therefore rate Niox Group PLC a Buy.